A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients With "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated
Latest Information Update: 05 Mar 2024
At a glance
- Drugs Cetuximab (Primary) ; Neratinib (Primary) ; Trastuzumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 28 Mar 2022 Planned End Date changed from 1 Jan 2022 to 30 Sep 2022.
- 28 Mar 2022 Status changed from recruiting to active, no longer recruiting.